^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:dubermatinib (TP-0903) (AXL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

    Excerpt:
    ...- Patients with AML and the presence of FLT3-ITD mutation...
    Trial ID:
    NCT04518345
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    JCI Insight
    Title:

    TP-0903 is active in models of drug-resistant acute myeloid leukemia

    Published date:
    12/03/2020
    Excerpt:
    TP-0903 demonstrated preclinical activity in AML models with FLT3-ITD and common co-occurring mutations in IDH2 and NRAS genes.
    DOI:
    10.1172/jci.insight.140169